{"id":15366,"date":"2015-05-08T08:35:21","date_gmt":"2015-05-08T08:35:21","guid":{"rendered":"http:\/\/demo.qodeinteractive.com\/bridge95\/?page_id=15366"},"modified":"2018-06-05T15:40:54","modified_gmt":"2018-06-05T13:40:54","slug":"the-agency","status":"publish","type":"page","link":"https:\/\/www.eurbg.org\/portal\/?page_id=15366","title":{"rendered":"Clinical Trials"},"content":{"rendered":"

[vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” padding_top=”84″ padding_bottom=”45″ css_animation=””][vc_column][vc_column_text]<\/p>\n

Current clinical trials in retinoblastoma include:<\/h3>\n

[\/vc_column_text][vc_separator type=”transparent” up=”43″ down=”0″][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”element_from_bottom” transition_delay=”150″ css=”.vc_custom_1464704350045{margin:20px; padding:20px;border-color: #ffae00 !important;border:solid;border-radius: 3px !important;}”][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
EudraCT Number:<\/b> 2011-006109-85
\nSponsor Protocol Number:<\/b> RTBAIEOP012
\nStart Date:<\/b> 2012-02-14
\nSponsor Name:<\/b>
\nA.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
\nFull Title:<\/b>
\nDIAGNOSTIC AND THERAPEUTIC STUDY FOR NEWLY DIAGNOSED RETINOBLASTOMA PATIENTS RTB AIEOP 012<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”43″ down=”0″][\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
Medical condition:<\/b>Newly diagnosed retinoblastoma patientsDisease:
\n<\/b>Version<\/b> 14.1
\nSOC Term<\/b> 10010331 - Congenital, familial and genetic disorders
\nClassification Code<\/b> 10038916
\nTerm<\/b> Retinoblastoma
\nLevel<\/b> PT
\n Age:<\/b> Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18
\nGender:<\/b> Male, Female
\nTrial protocol:<\/b> IT (Ongoing)Trial results:<\/b> (No results available)<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”60″ down=”0″][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”element_from_bottom” transition_delay=”150″ css=”.vc_custom_1464704350045{margin:20px; padding:20px;border-color: #ffae00 !important;border:solid;border-radius: 3px !important;}”][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
Clinical trial Number:<\/b> NCT02329002
\nFull Title: <\/b>Multicentric implementation of MR imaging in irradiated hereditary RB survivors<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”43″ down=”0″][\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
Objective:<\/b>For the evaluation of the value of craniofacial MRI screening for early detection of second craniofacial primary tumours and to enhance survival
\nStatus:<\/b>Not recruiting
\n Prinicipal investigator <\/b>Pim de Graaf <\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”60″ down=”0″][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”element_from_bottom” transition_delay=”150″ css=”.vc_custom_1464704350045{margin:20px; padding:20px;border-color: #ffae00 !important;border:solid;border-radius: 3px !important;}”][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
RB-Registry: clinical registry for prospective data on retinoblastoma epidemiology and clinical course
\n<\/b> Funded by Deutsche Kinderkrebsstiftung. Our aim with the RB-Registry is to gather epidemiological and clinical data on pediatric eye tumors to develop a knowledge base. The knowledge gathered within RB-Registry will improve counseling for newly diagnosed patients and will provide a base for the development of interventional clinical trials to improve early diagnosis, treatment and follow-up for retinoblastoma patients. RB-Registry provides a consultation hotline and reference evaluations. The database and a biobank will support accompanying biological studies. The long-term perspective of RB-Registry is to improve survival rates in advanced tumor stages to reduce late effects and improve the quality of life of survivors. <\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”43″ down=”0″][\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
Inclusion criteria:<\/b>Patients newly diagnosed with retinoblastoma or other pediatric eye tumors and children with newly diagnosed RB1 germline mutation who are residents of Germany and Austria and have not received prior treatment for retinoblastoma
\n Objectives:<\/b>The primary objective is to evaluate the exact retinoblastoma group (ICRB) and stage (IRSS) distribution in Germany and Austria
\nPrinicpal Investigator: <\/b> Dr Petra Temming<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”60″ down=”0″][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”element_from_bottom” transition_delay=”150″ css=”.vc_custom_1464704350045{margin:20px; padding:20px;border-color: #ffae00 !important;border:solid;border-radius: 3px !important;}”][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
EudraCT Number:<\/b> 2009-016448-38
\nSponsor Protocol Number:<\/b> IC 2009-04
\nStart Date:<\/b> 2009-12-15
\nSponsor Name:<\/b>
\nInstitut Curie
\nFull Title:<\/b>
\nTraitement adjuvant dans les r\u00e9tinoblastomes unilat\u00e9raux \u00e9tendus \u00e9nucl\u00e9\u00e9s d\u2019embl\u00e9e.<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”43″ down=”0″][\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
Medical condition:<\/b>
\nR\u00e9tinoblastomes unilat\u00e9raux \u00e9tendus \u00e9nucl\u00e9\u00e9s d\u2019embl\u00e9e.
\nDisease:<\/b>
\nVersion<\/b> 12.0
\nSOC Term<\/b>
\nClassification Code<\/b> 10038916
\nTerm<\/b> Retinoblastoma
\nLevel<\/b> LLT
\nPopulation Age:<\/b> Newborns, Infants and toddlers, Children, Under 18
\nGender:<\/b> Male, Female
\nTrial protocol:<\/b> FR (Ongoing)
\nTrial results:<\/b> (No results available)
\n<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”60″ down=”0″][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”element_from_bottom” transition_delay=”150″ css=”.vc_custom_1464704350045{margin:20px; padding:20px;border-color: #ffae00 !important;border:solid;border-radius: 3px !important;}”][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
EudraCT Number:<\/b> 2012-002825-31
\nSponsor Protocol Number:<\/b> : INTV-STC-RT-SI-2012
\nStart Date:<\/b> 2012-07-01
\nSponsor Name:<\/b>
\nAZIENDA OSPEDALIERA SENESE
\nFull Title:<\/b>
\nNEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: INTRAVITREAL AND SUBCONJUNCITIVAL INJECTION OF CHEMOTHERAPY in the intraoculars RTBs<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”43″ down=”0″][\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
Medical condition:<\/b>
\npatients with RTB
\nDisease:<\/b>
\nVersion<\/b> 14.1
\nSOC Term<\/b>10015919 - Eye disorders
\nClassification Code<\/b> 10030054
\nTerm<\/b> Ocular neoplasms
\nLevel<\/b> HLGT<\/p>\n

<\/h5>

<\/p><\/div><\/div><\/div>

<\/i><\/span><\/div>
Disease:<\/b>
\nVersion<\/b> 14.1
\nSOC Term<\/b>10015919 - Eye disorders
\nClassification Code<\/b> 10015919
\nTerm<\/b> Eye disorders
\nLevel<\/b> SOC
\nPopulation Age:<\/b>Newborns, Infants and toddlers, Children, Under 18
\nGender:<\/b> Male, Female
\nTrial protocol:<\/b> FR (Ongoing)
\nTrial results:<\/b> (No results available)
\n<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”60″ down=”0″][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”element_from_bottom” transition_delay=”150″ css=”.vc_custom_1464704350045{margin:20px; padding:20px;border-color: #ffae00 !important;border:solid;border-radius: 3px !important;}”][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
EudraCT Number:<\/b> 2016-001060-11
\nSponsor Protocol Number:<\/b> : FSJD-RTB-2015
\nStart Date:<\/b> 2017-08-03
\nSponsor Name:<\/b>Fundaci\u00f3 Sant Joan de D\u00e9u
\nFull Title:<\/b>A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma<\/h5>[vc_separator type=\"small\" position=\"left\" color=\"\" thickness=\"2\" width=\"20\" up=\"0\" down=\"15\"]

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”43″ down=”0″][\/vc_column_inner][vc_column_inner width=”1\/2″]

<\/i><\/span><\/div>
Medical condition:<\/b>refractory retinoblastoma Disease:<\/b>Version<\/b> 14.1 SOC Term<\/b>10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) Classification Code<\/b> 10038916 Term<\/b> RetinoblastomaLevel<\/b> PT<\/h5>

<\/p><\/div><\/div><\/div>[vc_separator type=”transparent” up=”60″ down=”0″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” padding_top=”84″ padding_bottom=”45″ css_animation=””][vc_column][vc_column_text] Current clinical trials in retinoblastoma include: [\/vc_column_text][vc_separator type=”transparent” up=”43″ down=”0″][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”element_from_bottom” transition_delay=”150″ css=”.vc_custom_1464704350045{margin:20px; padding:20px;border-color: #ffae00 !important;border:solid;border-radius: 3px !important;}”][vc_column_inner width=”1\/2″][vc_separator type=”transparent” up=”43″ down=”0″][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_separator type=”transparent” up=”60″ down=”0″][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”element_from_bottom” transition_delay=”150″ css=”.vc_custom_1464704350045{margin:20px;…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"full_width.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.eurbg.org\/portal\/index.php?rest_route=\/wp\/v2\/pages\/15366"}],"collection":[{"href":"https:\/\/www.eurbg.org\/portal\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.eurbg.org\/portal\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.eurbg.org\/portal\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eurbg.org\/portal\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15366"}],"version-history":[{"count":25,"href":"https:\/\/www.eurbg.org\/portal\/index.php?rest_route=\/wp\/v2\/pages\/15366\/revisions"}],"predecessor-version":[{"id":16011,"href":"https:\/\/www.eurbg.org\/portal\/index.php?rest_route=\/wp\/v2\/pages\/15366\/revisions\/16011"}],"wp:attachment":[{"href":"https:\/\/www.eurbg.org\/portal\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}